132,994 Shares in Enovis Corporation $ENOV Purchased by Legal & General Group Plc

Legal & General Group Plc acquired a new stake in shares of Enovis Corporation (NYSE:ENOV) during the second quarter, Holdings Channel.com reports. The firm acquired 132,994 shares of the company’s stock, valued at approximately $2,753,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. The Manufacturers Life Insurance Company purchased a new position in Enovis in the 2nd quarter worth about $552,000. Paradigm Capital Management Inc. NY bought a new position in Enovis in the 2nd quarter worth about $28,533,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Enovis during the second quarter worth approximately $207,000. Allworth Financial LP bought a new stake in shares of Enovis during the second quarter valued at approximately $36,000. Finally, Tejara Capital Ltd bought a new stake in shares of Enovis during the second quarter valued at approximately $644,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Price Performance

Shares of ENOV stock opened at $18.58 on Friday. Enovis Corporation has a 1-year low of $18.52 and a 1-year high of $34.28. The stock’s 50-day moving average is $25.50 and its 200 day moving average is $24.20. The company has a market cap of $1.07 billion, a P/E ratio of -0.96 and a beta of 1.31. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts predict that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on ENOV shares. BMO Capital Markets set a $27.00 price objective on Enovis in a research note on Tuesday. Evercore set a $32.00 target price on Enovis in a research report on Monday, July 6th. Citizens Jmp lowered their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Wednesday. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Finally, Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.38.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Insider Buying and Selling

In other news, insider Oliver Engert acquired 5,140 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were purchased at an average price of $19.46 per share, with a total value of $100,024.40. Following the transaction, the insider directly owned 61,238 shares in the company, valued at approximately $1,191,691.48. This represents a 9.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The shares were purchased at an average price of $19.15 per share, with a total value of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 23,833 shares of company stock worth $469,455. Insiders own 2.90% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.